The Global Allergy & Airways Patient Platform (GAAPP) is pleased to announce that Ruth Tal-Singer, Ph.D., will join as Chief Scientific Officer effective today, Friday, 26 May 2023.

“Ruth’s passion for research and dedication to the lung health community has been evident over the past thirty years, and we are delighted to have her as part of our team,”

Tonya Winders, President of GAAPP

Before joining GAAPP, Tal-Singer was Vice President of Respiratory Medical Innovation R&D Value Evidence & Outcomes and Senior Fellow at GSK Pharmaceuticals. During her career with GSK, she led many projects that resulted in new insights, bringing new treatments to the market. She also formerly served as Chief scientific officer and CEO of the COPD Foundation, where she led the patient-centered research, education, and global community outreach advocacy organization focused on the prevention and early diagnosis and treatment of chronic lung diseases. In fact, her vision led to the creation of World Bronchiectasis Day, observed on July 1. Tal-Singer’s idea resulted in global awareness of the under-researched and under-represented bronchiectasis disease in partnership with 20 other global patient advocacy, academic, and research organizations.

As GAAPP’s CSO, Tal-Singer will lead its scientific and medical advisory board while supporting ongoing research initiatives in allergic and airway diseases like asthma, COPD, and more.

Please join us in congratulating Ruth Tal-Singer on this new global role with GAAPP.